Traumatic Brain Injury Articles & Analysis
48 news found
Carleton Hsia, NanoBlood: NanoBlood LLC has developed VitalHemeTM (nanoRBC), an innovative multifunctional neurovascular protective agent for the prevention and treatment of ischemia, reperfusion injury and damaging inflammatory reactions caused by superoxide generation. ...
(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical Care Society’s (NCS) 20th Annual Meeting held in San Antonio, Texas on October 17 – 21, 2022 on the possible role of gammaCore (nVNS) in the acute treatment of Traumatic Brain Injury (TBI). The ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury ...
” Although stroke is the most common cause, aphasia can also occur due to traumatic brain injury or neurodegenerative disorders. There are two main types of aphasia. ...
ByBioMedSA
Even more noteworthy, results from the studies revealed that KLS-13019 did not bind to opioid receptors in the brain, meaning it holds a very low risk for chemical dependency. “Following our recent grant award from the National Institute of Health – National Institute of Neurological Disorders and Stroke (NIH-NINDS), under the HEAL initiative, these results are ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury ...
CINCINNATI, OH – March 30, 2022 – Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, has been selected to participate in the Mayo Clinic and Arizona State University MedTech Accelerator. The flagship program of the Mayo Clinic and ASU Alliance for Health Care was designed to provide early-stage medical device and ...
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. ...
Under the PCT Patent, Neuropathix novel therapeutic compounds have the potential to target diseases that include neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, ...
Millions of people rely on self-catheterization to empty their bladder due to conditions such as urinary bladder retention, spinal cord injury, traumatic brain injury, multiple sclerosis, and more. If you are an uncoated straight catheter user, a high-quality sterile catheter lubricant is an important addition to your catheter ...
The therapeutic targets include CIPN, a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and ...
While many people who suffer a concussion receive no medical attention, an average of 283,000 emergency department visits per year for sports and recreation–related traumatic brain injuries occurred among children during 2010 – 2016. ...
BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild traumatic brain injuries (mTBIs), including brain bleed and concussion. ...
“More than four million patients seek care each year at hospital emergency departments for mild traumatic brain injuries. BrainScope is the only FDA-cleared technology that can objectively assess both brain bleeds and concussions in minutes and bring the needed diagnostic insights to help steer these patients to appropriate ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury ...
NeuSTAT™ is currently in a pivotal trial for continuous monitoring of brain injury in an acute care setting. NeuroHawk™ EMS (expected to begin pivotal trial in 2022) is being developed as a triage tool for first responders, enabling detection of traumatic brain injury and stroke by subtype. ...
More than 400,000 military personnel have suffered at least one traumatic brain injury in the last two decades. Long-term consequences for patients may have been better if doctors could more quickly have diagnosed the situation and treated it. ...
Department of Defense will accelerate development of a new rapid, noninvasive brain scanner that can detect and continuously monitor traumatic brain injury in a battlefield or field environment. ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury ...